Neximmune Historical Income Statement
| NEXI Stock | USD 3.26 0.17 4.96% |
Historical analysis of Neximmune income statement accounts such as Selling General Administrative of 13.7 B can show how well Neximmune performed in making a profits. Evaluating Neximmune income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Neximmune's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Neximmune latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neximmune is a good buy for the upcoming year.
Neximmune |
About Neximmune Income Statement Analysis
Neximmune Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Neximmune shareholders. The income statement also shows Neximmune investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Neximmune Income Statement Chart
Neximmune Income Statement is one of the three primary financial statements used for reporting Neximmune's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Neximmune revenue and expense. Neximmune Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Neximmune's Other Operating Expenses is increasing as compared to previous years. The Neximmune's current Research Development is estimated to increase to about 26.4 M, while Depreciation And Amortization is projected to decrease to under 702.8 K. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Neximmune. It is also known as Neximmune overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Neximmune's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Neximmune current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neximmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.As of now, Neximmune's Other Operating Expenses is increasing as compared to previous years. The Neximmune's current Research Development is estimated to increase to about 26.4 M, while Depreciation And Amortization is projected to decrease to under 702.8 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 861.4K | 576.7K | 1.0M | 702.8K | Interest Income | 52.5K | 664.4K | 973.3K | 1.0M |
Neximmune income statement Correlations
Click cells to compare fundamentals
Neximmune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neximmune income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 246.8K | (1.7M) | (852.8K) | 664.4K | 973.3K | 1.0M | |
| Interest Income | 246.8K | 20.8K | 52.5K | 664.4K | 973.3K | 1.0M | |
| Depreciation And Amortization | 436.4K | 729.6K | 861.4K | 576.7K | 1.0M | 702.8K | |
| Selling General Administrative | 5.7M | 10.0M | 15.8M | 15.9M | 13.0B | 13.7B | |
| Other Operating Expenses | 20.9M | 27.9M | 53.3M | 63.1M | 29.2M | 38.0M | |
| Operating Income | (20.9M) | (27.9M) | (53.3M) | (63.1M) | (29.2M) | (30.7M) | |
| Net Income From Continuing Ops | (20.5M) | (29.9M) | (50.9M) | (62.5M) | (43.9M) | (46.1M) | |
| Ebit | (20.9M) | (27.9M) | (53.3M) | (63.1M) | (29.2M) | (30.7M) | |
| Research Development | 15.2M | 17.8M | 37.5M | 47.1M | 18.3M | 26.4M | |
| Ebitda | (20.4M) | (27.1M) | (52.4M) | (62.5M) | (28.2M) | (29.6M) | |
| Total Operating Expenses | 20.9M | 27.9M | 53.3M | 63.1M | 28.2M | 37.9M | |
| Reconciled Depreciation | 436.4K | 619.0K | 870.3K | 994.8K | 1.1M | 767.4K | |
| Income Before Tax | (20.5M) | (29.9M) | (50.9M) | (62.5M) | (32.3M) | (34.0M) | |
| Total Other Income Expense Net | 339.1K | (2.0M) | 2.4M | 576.7K | (3.2M) | (3.0M) | |
| Net Income Applicable To Common Shares | (23.2M) | (33.1M) | (51.3M) | (62.5M) | (56.3M) | (59.1M) | |
| Net Income | (20.3M) | (31.6M) | (51.7M) | 514.2M | (32.3M) | (30.7M) | |
| Income Tax Expense | (246.8K) | 1.8M | 843.9K | (576.7M) | (2.0) | (2.1) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neximmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Neximmune Stock analysis
When running Neximmune's price analysis, check to measure Neximmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neximmune is operating at the current time. Most of Neximmune's value examination focuses on studying past and present price action to predict the probability of Neximmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neximmune's price. Additionally, you may evaluate how the addition of Neximmune to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Neximmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neximmune. If investors know Neximmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neximmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (30.82) | Return On Assets (0.71) | Return On Equity (1.81) |
The market value of Neximmune is measured differently than its book value, which is the value of Neximmune that is recorded on the company's balance sheet. Investors also form their own opinion of Neximmune's value that differs from its market value or its book value, called intrinsic value, which is Neximmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neximmune's market value can be influenced by many factors that don't directly affect Neximmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neximmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neximmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neximmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.